Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author(s):
Kater, A.P.; Oers, M.H.J. van; Norden, Y. van; Straten, L. van der; Driessen, J.; Posthuma, W.F.M.; Schipperus, M.; Chamuleau, M.E.D.; Nijland, M.; Doorduijn, J.K.; Gelder, M. van; Hoogendoorn, M.; Croon, F. de; Wittebol, S.; Kerst, J.M.; Marijt, E.W.A.; Raymakers, R.A.P.; Schaafsma, M.R.; Dobber, J.A.; Kersting, S.; Levin, M.D.; HOVON CLL Study Grp
Published
2019
Publication type
Article / Letter to editor
Date issued
2019-01-31
Language
English
Is part of
Haematologica (2019), Vol. 104, no. 1, p. 147-154
hdl
1887/119666
doi
10.3324/haematol.2018.193854